HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot could stop dangerous swelling attacks in HAE
Disease control OngoingThis Phase 3 trial tests whether navenibart, a drug given as a shot under the skin, can prevent attacks in people with hereditary angioedema (HAE). About 145 adults and teens with HAE type 1 or 2 will receive either navenibart or a placebo for 6 months. The main goal is to see if…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for HAE: Long-Term trial of navenibart launches
Disease control ENROLLING_BY_INVITATIONThis Phase 3 trial tests the long-term safety and effectiveness of navenibart, an injectable drug, in 145 adults and teens with hereditary angioedema (HAE) who were in a previous study. The trial has two parts: first, everyone gets a fixed dose; then, some may switch to a persona…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for HAE patients: experimental drug aims to slash attack rate
Disease control OngoingThis study tests an experimental drug called BW-20805 in 25 adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug can reduce how often attacks happen over about 6 months. Participants must have had at least 2 att…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE2 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder
Disease control OngoingThis study follows 155 people in Japan with hereditary angioedema (HAE) who are taking TAKHZYRO (lanadelumab) injections every two weeks. Researchers will monitor side effects and check if the drug helps control swelling attacks over 12 months. The goal is to see how well TAKHZYR…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New daily pill could stop painful swelling attacks for HAE patients
Disease control OngoingThis Phase 3 trial tests whether a once-daily pill called deucrictibant can prevent sudden swelling attacks in people aged 12 and older with hereditary angioedema (HAE). Participants receive either the drug or a placebo for 24 weeks, and researchers count how many attacks occur. …
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New pill could stop dangerous swelling attacks in hereditary angioedema
Symptom relief ENROLLING_BY_INVITATIONThis study tests a pill called deucrictibant for quickly treating swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have had HAE attacks before will take the drug as needed and be monitored for safety and…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data on HAE drug lanadelumab: does it cut attacks?
Knowledge-focused OngoingThis study follows 50 people in the UK with hereditary angioedema (HAE) types I or II who are taking lanadelumab. Researchers will compare the number of HAE attacks in the year before starting the drug to up to two years after. The goal is to see how well the drug works outside o…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC